| HOME >> MEDICINE >> TECHNOLOGY |
The VAP Test provides researchers and medical professionals with direct measurement of LDL, HDL and all relevant subclasses, and includes non-HDL, a highly accurate determination of apoB, and emerging risk factors (such as Lp(a), remnants, and small dense LDL.)
"This indicates that even patients whose cholesterol results appear normal or who are on therapy may still harbor a significant atherogenic burden leading to the development of vulnerable plaques and narrowed arteries," said James Ehrlich, M.D., Atherotech's chief medical officer. "For the clinician, this demonstrates the value of identifying and lowering the substantial residual risk that remains despite aggressive statin monotherapy. A key feature of the comprehensive VAP Test is the identification of the major lipid components of residual risk leading to proper individualized therapy."
VAP technology has been used in more than 100 clinical trials and will continue to play an important role in clinical practice and -- as demonstrated by the present study -- as a valuable analytical research tool. The VAP Test is available nationwide. For more information on the VAP Test for research and clinical trial applications, call 877.901.8510 or e-mail research@atherotech.com.
About Atherotech, Inc.
Atherotech is a cardio-diagnostic company focusing on direct
measurement of the comprehensive lipid panel using the company's patented
VAP Technology. The VAP Test directly measures the cholesterol content of
all lipids, components and subclasses. It is the first cholesterol profile
to comply with updated National Cholesterol Education Program ATP III
recomme
'/>"/>
| SOURCE Atherotech, Inc. Copyright©2008 PR Newswire. All rights reserved |